Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00401726|
Recruitment Status : Completed
First Posted : November 20, 2006
Results First Posted : June 29, 2010
Last Update Posted : April 23, 2012
|Condition or disease||Intervention/treatment||Phase|
|Depressive Disorder, Major||Drug: Venlafaxine ER Behavioral: Dialogues Time to Talk Program||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||537 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Patient Outcomes With Education, Drug Therapy, and Support (POETS): A Multicenter, Open-label, Randomized Study to Evaluate Depressed Subjects Treated With Venlafaxine Extended-release vs. Venlafaxine Extended-release Plus the Dialogues Time to Talk Program in a Primary Care Setting|
|Study Start Date :||June 2006|
|Actual Study Completion Date :||October 2007|
- Number of Patients Responding "Very Satisfied" on Satisfaction With Depression Care Scale (SDCS) [ Time Frame: 112 days ]Patient satisfaction with depression care treatment was evaluated by patient self-assessment using the SDCS, a 10-point visual analog scale (0=not at all satisfied, 10=extremely satisfied). "Very satisfied" was defined as a score of greater than or equal to 8.
- Change in 17-item Hamilton Depression Scale Score From Baseline to 16 Weeks [ Time Frame: Baseline and 112 days ]HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on a 0 to 2 or 4 scale (0 = none/absent and 4 = most severe) with a maximum total score of 50. Change = 16 week adjusted mean HAM-D17 score minus baseline.
- Patient Global Impression of Improvement (PGI-I) Score [ Time Frame: 112 days ]PGI-I is a global rating scale that measures disease improvement. Using a 7-point scale (1=very much improved, 7=very much worse), the patients rate how much their illness has improved or worsened relative to their baseline status.
- Change in WHO 5-item Well Being Index Score From Baseline to 16 Weeks [ Time Frame: Baseline and 112 days ]WHO 5-item Well Being Index (WHO-5) evaluates positive psychological well-being. WHO-5 consists of 5 questions and each is rated on a 6-point scale. The total score ranges from 0 to 25 (0=worst possible quality of life, 25=best possible quality of life). Change = 16 week adjusted mean WHO-5 score minus baseline.
- Number of Patients Compliant With Therapy [ Time Frame: 112 days ]Patient compliance with therapy was assessed using a Medical Adherence Questionnaire (MAQ). MAQ consisted of 5 levels of compliance with taking medicine: Never miss, Sometimes miss, Miss half of the time, Miss most of the time, Always miss. Compliance with therapy was defined as a response of "Never miss" or "Sometimes miss".
- Change in Inventory of Depressive Symptomatology - Self-Report (IDS-SR) Score From Baseline to 16 Weeks [ Time Frame: Baseline and 112 days ]IDS-SR is a patient self-administered tool used to measure the severity of depressive symptoms. Each symptom is assessed on a scale of 0 to 3 (0=absence of symptom to 3=sever symptom) for a total maximum score of 84.
- Change in Sheehan Disability Scale Score From Baseline to 16 Weeks [ Time Frame: Baseline and 112 days ]The Sheehan Disability Scale is a self-administered tool that measures functional impairment in 3 domains: Work/School, Social Life and Family Life/Home Responsibilities. The patient rates the extent to which each of these domains are impaired by his/her symptoms using a 10 point visual analog scale: (0=not at all impaired and 10=extremely impaired) for a total maximum score of 30.
- Number of Patients by Clinical Global Improvement - Global Improvement Score at 16 Weeks [ Time Frame: 112 days ]CGI-I is a global rating scale that measures disease improvement. Using a 7-point scale, the clinician rates how much the patient's illness has improved or worsened relative to the baseline status (1=very much improved, 7=very much worse).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00401726
Show 44 Study Locations
|Study Director:||Medical Monitor||Wyeth is now a wholly owned subsidiary of Pfizer|